share_log

Cantor Fitzgerald Maintains Overweight on Mesoblast, Lowers Price Target to $17

Cantor Fitzgerald Maintains Overweight on Mesoblast, Lowers Price Target to $17

坎託·菲茨傑拉德維持對Mesoblast的增持,將目標股價下調至17美元
Benzinga ·  2023/08/31 09:19

Cantor Fitzgerald analyst Louise Chen maintains Mesoblast (NASDAQ:MESO) with a Overweight and lowers the price target from $23 to $17.

Cantor Fitzgerald分析師Louise Chen維持中胚層(納斯達克:MESO)增持,並將目標價從23美元下調至17美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論